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Background and Objectives: This systematic review and meta-analysis of randomized controlled trials (RCTs) aims to assess
efficacy and safety of tranexamic acid (TXA) use in acute traumatic injuries.
Methods: PubMed and Cochrane libraries were searched for relevant RCTs published between January 2011 and January 3, 2021.
Cohen’s Q Test for heterogeneous effects was used to determine the appropriateness of fixed versus random effects models.
Results: Twenty-two studies met inclusion criteria. Meta-analysis of relative risk of mortality between treatment and placebo groups
in the in-hospital, and perioperative settings was not significant. However, the risk of mortality is significantly lower in the treatment
versus placebo group when TXA was given as loading dose only. Ten of the 11 studies evaluating perioperative use of TXA included
in systematic review found significantly lower blood loss in the treatment compared with placebo groups, but results of meta-analysis
showed no significant difference. Results of meta-analysis indicate that the risk of venous thromboembolism (VTE) in the in-hospital
treatment group is greater than that of the placebo. In subset analysis of studies using only a single loading dose, there were no
significant differences in VTE.
Conclusions: Systematic review supports TXA benefits are most evident when given shortly after injury and meta-analysis supports
TXA reduces mortality as a single loading dose. Systematic review supports perioperative use of TXA when large volume blood loss
is anticipated. Meta-results showed no significant difference in risk of thromboembolism in single-dose TXA treatment compared with
placebo. These findings suggest that TXA is safe and effective for control of traumatic bleeding.
Keywords: tranexamic acid prehospital use, tranexamic acid in-hospital use, tranexamic acid perioperative use, acute trauma,
outcomes measures

INTRODUCTION

is secondary to traumatic brain injury (TBI) or hemorrhage.3,4
Tranexamic acid (TXA) inhibits fibrinolysis, strengthens clot
formation, and reduces overall incidence of trauma-induced
coagulopathy.5 TXA is a competitive inhibitor of plasminogen,
which stops enzymatic breakdown of fibrin by plasmin, thereby
facilitating secondary hemostasis.6
The CRASH-2 and CRASH-3 trials showed a significant
reduction in mortality with administration within 3 hours
of injury.7,8 However, concerns exist about the risk of venous
thromboembolic (VTE) events (e.g., pulmonary embolism [PE],
deep vein thrombosis [DVT]).9 Prehospital TXA administration
was evaluated in the STAAMP trial, which showed mortality
benefit in patients with severe shock who received TXA within 1
hour of injury and benefit with dosages higher than standard.10

Traumatic injury is the leading cause of death in the United
States among those aged ≤45 years.1,2 Most commonly, death
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Objectives
This systematic review and meta-analysis aims to investigate the
safety and efficacy of TXA use in acute traumatic injury through
review of recent placebo controlled randomized clinical trials
(RCTs) by assessing quantitative clinical outcomes in the prehospital, in-hospital, and perioperative settings.
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Population, Intervention, Comparator, and Outcomes

Annals of Surgery (2021) 4:e105

PICO 1

Received: 5 May 2021; Accepted 26 September 2021

In adult trauma patients without TBI, is prehospital use of TXA
associated with lower incidence of mortality, complication rates,
and blood loss?
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PICO 2

analyzed to determine the effect of ISS, TXA administration setting/dosage, and by severity of TBI as evaluated by GCS.

In adult trauma patients without TBI, is in-hospital only use of
TXA associated with lower incidence of mortality, complication
rates, and blood loss?

Meta-analysis
Meta-analysis was performed in MS Excel 2010 and MATLAB
2019b using our internal formulas and functions.13 In cases comparing occurrence rates of TXA-treated patients versus placebo,
relative risk (RR) was chosen as the metric of comparison due to
its relatively direct interpretation. In all cases, meta-analysis was
performed only when more than three studies were included in a
given subcategory. To properly assess RR, the number of events of
interest in both TXA and Control groups needed to be at least one.
In all cases, the Cohen’s Q test for heterogeneous effects was used
to determine the appropriateness of fixed versus random effects
models. Finally, all significance levels were defined as P < 0.05
and all confidence intervals (CI) were calculated using 95% CI.
Summary of population, intervention, comparator, and outcomes
(PICO) questions and location of results are shown in Figure 1.

PICO 3
In adult trauma patients without TBI, is perioperative only use
of TXA associated with lower incidence of mortality, complication rates, and blood loss?
PICO 4
In adult trauma patients with TBI, is use of TXA associated with
lower incidence of mortality, complication rates, and blood loss?

METHODS
Data Sources and Search Strategy
This study was completed according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.11 PubMed and Cochrane databases were searched
for studies published between January 1, 2011, and January 3,
2021. The following search keywords were included: “trauma”
AND “tranexamic acid” AND “traumatic brain injury,”
“trauma” AND “tranexamic acid” AND “blunt,” “trauma”
AND “tranexamic acid” AND “penetrating” “trauma” AND
“tranexamic acid” AND “prehospital.” Studies not published in
the English language were excluded. Studies were first screened
by title and abstract, then by full text. A final literature search
was performed on January 3, 2021.

RESULTS
Systematic Review
Initial literature search of PubMed and Cochrane databases
identified 1,205 publications. After removal of duplicates,
873 studies remained. Studies not published in English were
excluded. After screening by title/abstract, there were 375 studies. Non-RCTs were excluded, resulting in 67 trials for fulltext review. Twenty-two RCTs met inclusion criteria and were
included for data extraction and meta-analysis (Fig. 2).8,10,14–33
Risk of Bias and Quality of Evidence Assessment
The quality of evidence was moderate (7 RCTs)16,18,19,24,27,30,32
or high (15 RCTs)10,12–15,17,20–23,25,26,28,29,31 (Table S1a, http://
links.lww.com/AOSO/A85). The risk of bias was low: 3 RCTs
reported small sample size, and 1 RCT reported 1 participant
lost to follow up (Table S1b, http://links.lww.com/AOSO/A85).

Study Selection and Eligibility Criteria
There were no limits on country of publication, TXA administration setting, route, dosage, or patient follow up. While there
were no limitations on patient age, included literature failed to
report significant data regarding TXA administration in pediatric trauma patients. Studies were excluded if quantitative
clinical outcomes were not reported. Surveys, editorials, commentary, and non-RCTs were excluded.

Systematic Review of Prehospital and In-Hospital Use of TXA
There were only two studies which evaluated TXA given both
prehospital and in-hospital.10,14 One study assessed use in nonTBI trauma patients.10 The other study included only patients
with TBI (Table S2, http://links.lww.com/AOSO/A85).14

Risk of Bias and Quality of Evidence Assessment
Quality of evidence for all included studies was assessed using
the Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) Working Group criteria.12 GRADE
criteria were also utilized to determine risk of bias.

Systematic Review of Prehospital and In-Hospital Use of
TXA in Non-TBI
Guyette et al analyzed the STAAMP trial, which evaluated the
effect of prehospital TXA on mortality among trauma patients
with risk of hemorrhage.10 This large, multicenter RCT enrolled
903 patients (Table S2, http://links.lww.com/AOSO/A85) from
four US level 1 trauma centers, and had either prehospital hypotension (SBP ≤ 90 mm Hg) or tachycardia (HR ≥ 110) <2 hours
from injury.10 Patients were randomized to receive either 1 g of
TXA or placebo by EMS.10 There was no difference in overall
30-day mortality (8.1% vs 9.9%, P = 0.17), but subgroup analysis showed statistically significant difference when TXA was
given within 1 hour of trauma (4.6% vs 7.6%; P < 0.002) or in
cases of severe shock (18.5% vs 35.5%; P < 0.003) (Table S3,
http://links.lww.com/AOSO/A85).10

Data Collection Process
The initial literature search was performed by S.E.R., A.E., I.Z.,
and A.L. and later screened by article title and abstract for exclusion. Authors S.E.R., A.E., I.Z., A.L., and M.A.A. performed secondary searches. The final literature search was conducted by A.E.
and S.E.R. for data extraction from full-text RCTs. Any discrepancies in screened and selected articles were reviewed and resolved
by A.E., M.M., and S.E.R. The extracted data included publication
year, patient population, patient demographics, the setting, route,
and dosage of TXA, fraction of patients with TBI, blood loss, units
of transfused blood, Glasgow Coma Scale (GCS), Injury Severity
Score (ISS), mortality, complications, and patient follow-up time.

Systematic Review of Prehospital and In-Hospital Use of
TXA in TBI

Outcome Measures
Primary outcome is in-hospital and 30-day mortality. Secondary
outcomes included complications such as DVT, PE, or stroke.
Tertiary outcomes included blood loss. Outcomes were further

Rowell et al evaluated field-use TXA in TBI among 966
patients.14 Participants with moderate-severe TBI without
2
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FIGURE 1. Summary of PICO questions and location of results. PICO, population, intervention, comparator, and outcomes.

Systematic Review of In-Hospital Use of TXA in Non-TBI

shock were recruited to the double-blind RCT from 20 United
States and Canadian trauma centers (Table S2, http://links.
lww.com/AOSO/A85).14 Participants were randomized into
three cohorts to receive 1 g prehospital TXA bolus plus an 8
hours maintenance infusion (bolus plus maintenance group),
2 g prehospital TXA bolus plus placebo infusion (bolus only
group), or placebo bolus prehospital plus placebo infusion
(placebo group).14 There was no statistically significant difference in positive neurological outcome (Glasgow Outcome
Scale-Extended [GOSE] score > 4) at 6-month follow up
(65% vs 62%; P = 0.84), in 28-day mortality (14% vs 17%;
P = 0.26), or growth of intracranial hemorrhage (ICH) (16%
vs 20%; P = 0.16) (Table S3, http://links.lww.com/AOSO/
A85).14

Monsef Kasmaei et al randomized 106 patients with pelvic trauma
to either 1 g intravenous TXA loading dose followed by 3 doses
every 8 hours versus placebo.22 The main aim was blood loss
reduction, evidenced by hemoglobin concentration (Tables S2 and
S3, http://links.lww.com/AOSO/A85). There were significant differences in hemoglobin concentrations between TXA and control
groups at 48 hours (11.58 vs 10.25; P = 0.0001) and 72 hours
(11.45 vs 9.83; P = 0.0001) after admission.22 No side effects were
reported by either group after being discharged from the hospital.22
In the study conducted by Spinella et al, 149 patients were
randomized to receive placebo, 2 g TXA, or 4 g TXA over 10
minutes.24 There were no significant differences in baseline
patient demographics, mortality (P = 0.81), or amount of blood
products given after TXA administration (P > 0.05) between
the groups.24 However, the difference in thromboembolic events
approached significance with increasing TXA dosage (placebo:
12.0%; 2 g: 26.5%; 4 g: 32.0%; P = 0.05).24

Systematic Review of In-Hospital Use of TXA
Nine studies evaluated TXA in the hospital setting.8,15,17,21–24,29,33
Of these, 7 evaluated use in patients with TBI (Table S2, http://
links.lww.com/AOSO/A85).8,15,17,21,23,29,33 The dosing protocol
for most of these studies included a loading bolus followed by
maintenance infusion. Two studies only administered a one-time
bolus of TXA.21,24

Systematic Review of In-Hospital Use of TXA in TBI
The CRASH-3 study examined the effect of TXA on TBI death
in 9,127 patients randomly assigned to receive treatment or
3
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FIGURE 2. PRISMA flow chart for randomized controlled trials included in the systematic review and meta-analysis.

placebo within 3 hours of injury. They found no evidence of
heterogeneity in the effect of TXA by patient age (P = 0.45).8
Among the patients, the risk of head injury-related death was
18.5% in the TXA group versus 19.8% with placebo (855 vs
892 events, RR: 0.94; 95% CI: 0.86, 1.02).8 In sensitivity analysis, which excluded patients with a GCS=3 or bilateral unreactive pupils at baseline, the risk was 12.5% versus 14% (485
vs 525 events, RR: 0.89; 95% CI: 0.80, 1.00).8 Additionally,
the CRASH-3 study found a reduction in the risk of head injury-related death with TXA in patients with mild-moderate head
injury (RR: 0.78; 95% CI: 0.64, 0.95), but in patients with
severe head injury they found no clear evidence of risk reduction
(RR: 0.99; 95% CI: 0.91, 1.07) (Tables S2 and S3, http://links.
lww.com/AOSO/A85).8

Early treatment was more effective than later treatment in
patients with mild-moderate head injury (P = 0.005), but no
obvious difference in patients with severe head injury (P = 0.73)
was found.8 In a regression analysis, when the effect of baseline GCS was examined, they found TXA was more effective in
less severely injured patients (P = 0.007) and reduced head injury-related deaths in those with reactive pupils (RR: 0.87; 95%
CI: 0.77, 0.98).8 Overall, when stratified by time to treatment,
no evidence of heterogeneity (P = 0.96) was recorded.8 The RR
of head injury-related death, regardless of injury severity, with
TXA was 0.96 (95% CI: 0.79, 1.17), 0.93 (95% CI: 0.85, 1.02),
and 0.94 (95% CI: 0.81, 1.09) in patients randomly assigned to
receive treatment within 1 hour, between 1 hour and 3 hours,
and over 3 hours after injury, respectively.8
4
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Regarding complications, the CRASH-3 study did not find
evidence of TXA increasing fatal or nonfatal stroke (RR: 1.08;
95% CI: 0.71, 1.64). Risk of seizure was similar between TXA
and placebo groups (RR: 1.09; 95% CI: 0.90, 1.33) (Table S3,
http://links.lww.com/AOSO/A85).8
Jokar et al evaluated the effect of TXA on ICH 48 hours
after injury in TBI with GCS > 8 (Table S2, http://links.lww.
com/AOSO/A85). Eighty patients were enrolled in the study and
randomly assigned to be given either placebo or TXA (1 g bolus
plus 1 g over 8 hours), and ICH was measured by CT scan. ICH
volume expansion was significantly less in the TXA group (1.7
vs 4.3 mL; P < 0.001).17 Mortality was not reported (Table S3,
http://links.lww.com/AOSO/A85).
Participants in the study conducted by Mojallal et al
received either 1 g TXA or placebo over 1 hour after admission and head CT (n = 120), within 8 hours of the trauma
(Table S2, http://links.lww.com/AOSO/A85).21 There was no
significant difference in mean cerebral hemorrhage volume
at admission and after 24 hours between treatment and placebo groups (P = 0.207 and P = 0.824, respectively) (Table S3,
http://links.lww.com/AOSO/A85).21 Similarly, there was no
significant difference in in-hospital mortality (P = 0.236).21 It
should be noted, however, that baseline ICH bleed types were
not similar and 16 patients were lost to follow up in the TXA
group and four in the control group.
Perel et al performed post-hoc analysis of 270 CRASH-2 TBI
participants from 10 hospitals.23 Fewer patients in the TXA
group had poor outcomes (significant hemorrhage growth, new
intracranial hemorrhage, new focal cerebral ischemic lesions,
need for neurosurgery, or death) compared with the placebo
group (OR: 0.59; 95% CI: 0.37, 0.96).23 The adjusted OR for
poor outcome was 0.57 (95% CI: 0.33, 0.98).23 Furthermore,
there were no adverse events related to the study treatment.23
Yutthakasemsunt et al performed a 238-patient double-blinded RCT evaluating TXA in reducing ICH for moderate-severe TBI (GCS 4-12).29 Patients (≥16 years) were divided
into a TXA arm (n = 120) receiving a 1 g loading dose over
30 minutes and a maintenance dose of 1 g over 8 hours, and
a placebo group with (n = 118).29 Primary outcome was ICH
expansion. Progression of ICH, GOSE, and death were not significantly different between the groups.29
Fakharian et al analyzed TXA (n = 74) versus placebo
(n = 75) in TBI patients aged ≥ 15 (Tables S2 and S3, http://links.
lww.com/AOSO/A85).15 The TXA group received an in-hospital
loading dose of 1 g and 1 g over 8 hours. There was no statistical
difference in new bleeds (P = 0.210), hematoma expansion (RR:
0.89; 95% CI: 0.55, 1.74), or need for surgery (RR: 0.67; 95%
CI: 0.29, 1.55).15 Unfavorable outcomes at discharge (RR: 0.62;
95% CI: 0.22, 1.46) and at 3 months (RR: 0.46; 95% CI: 0.16,
1.26) were similar.15 Finally, mortality between both groups was
similar (RR: 0.67; 95% CI: 0.12, 3.93).15 There was, however, a
significant difference in the change in hemorrhage volume, with
68.5% of the TXA patients experiencing a decrease compared
with 50.7% in placebo (P = 0.03).15
Chakroun-Walha et al assessed TXA use in 180 TBI patients
with no extracranial hemorrhage.33 Ninety-six patients were
randomized to receive a loading dose of 1 g TXA, followed by
1 g over 8 hours, but only 10% received TXA within 3 hours of
injury.33 Transfusion requirements were similar through hospital
day 7, and there was no significant difference in need for neurosurgical intervention, mortality, or GOSE at 28 days.33 There
was a significantly higher rate of PE in the TXA group (11.5%
vs 2.4%; P = 0.02).33

bolus.16,18,20,26,28,31,32 Three administered two identical doses of
TXA.25,27,30 One gave a loading dose followed by maintenance
dose of TXA.19
Tengberg et al recruited 72 patients to their RCT evaluating
perioperative TXA in unstable extracapsular hip fractures.26
Patients were randomized to receive TXA (n = 33) or placebo
(n = 39).26 The TXA cohort was given a preoperative bolus of
1 g TXA and a postoperative infusion of 3 g over 24 hours.26
The TXA cohort had a 90-day mortality rate of 39% and the
placebo cohort had a mortality rate of 10.2% (P = 0.07).26 The
TXA cohort had a recorded blood loss of 1,529.6 mL while
the placebo cohort had a recorded blood loss of 2,100.4 mL
(P = 0.029).26
Watts et al evaluated perioperative TXA use in 138 patients
undergoing arthroplasty for low energy isolated femoral neck
fracture, divided into TXA (n = 69) or placebo (n = 69) groups
(Table S2, http://links.lww.com/AOSO/A85).27 The TXA cohort
received a perioperative dose of 15 mg/kg TXA and a second
dose after wound closure.27 Blood loss in the TXA cohort was
lower throughout postoperative days (POD) 1 (731 vs 973 mL;
P = 0.01), 2 (830 vs 1124 mL; P = 0.0002), and 3 (902 vs
1205 mL; P = 0.0005) (Table S3, http://links.lww.com/AOSO/
A85).27
Xie et al assessed TXA in patients undergoing calcaneal fracture surgery, randomized into 2 cohorts of 45 patients.28 The
treatment group received a perioperative dose of 15 mL/kg.28
The control group demonstrated lower incidence of wound
complications (3 vs 10 patients, 7.3% vs 23.8%, P = 0.036).28
Vascular events such as DVT, MI, and CVA were similar (Table
S3, http://links.lww.com/AOSO/A85).28 There were significant
differences in postoperative blood loss between the two groups
(110.0 mL in TXA vs 320.0 mL placebo; P < 0.001).28
Zhang et al evaluated TXA use in patients receiving nail
fixation of intertrochanteric femur fractures.30 They recruited
122 participants, randomized into two groups of 61. The treatment group received two doses of 1 g TXA over 10 minutes.30
There was no significant difference in mortality between TXA
and placebo (1.6% vs 3.3%; P = 1.000). The TXA group had
lower blood loss (712.11 mL) compared with the placebo group
(1,103.5 mL; P < 0.001).30
Zhou et al also evaluated TXA in intertrochanteric fractures.31
Fifty patients were randomized to receive 1 g TXA before proximal femoral surgery and 50 received placebo.31 There were no
statistical differences between the groups for DVT (P = 0.65) or
PE (P = 0.31). Blood loss was significantly lower in TXA group
(563.37 vs 819.25 mL, 95% CI: −349.49, 162.27; P < 0.01)
(Table S3, http://links.lww.com/AOSO/A85).31
Lack et al evaluated perioperative TXA in open reduction
and internal fixation (ORIF) of acetabular fractures.19 They
recruited 88 patients from 2 US level 1 trauma centers, randomized to receive either TXA (n = 42) or placebo (n = 46)
in a 10 mg/kg bolus 30 minutes before surgery, plus 10 mg/kg
IV intraoperatively (Tables S2 and S3, http://links.lww.com/
AOSO/A85).19 There was no significant difference in blood loss
(753 vs 533 mL; P = 0.061), transfusion rate (50% vs 32.6%;
P = 0.097), or transfusion requirements (average of 2.65 vs
2.36 units; P = 0.522) (Table S3, http://links.lww.com/AOSO/
A85).19Khiabani et al examined perioperative TXA in ORIF for
bilateral displaced mandibular fractures18 from a center in Iran
(Table S2, http://links.lww.com/AOSO/A85). Participants were
randomized into equal-sized cohorts receiving either 20 mg/kg
of TXA or placebo prior to surgery.18 They found that mean
blood loss was significantly lower in the TXA group (360.57
± 173.5 mL and 560.9 ± 248.07 mL, respectively; P = 0.008)
(Table S3, http://links.lww.com/AOSO/A85).18
Lei et al evaluated perioperative TXA in surgical repair of
traumatic intertrochanteric fracture; 77 participants were
recruited to this single-blind study and randomized to receive
either 1 g of TXA or placebo.20. There was significantly lower

Systematic Review of Perioperative Use of TXA
A total of 11 studies evaluated perioperative TXA use (Tables
S2 and S3, http://links.lww.com/AOSO/A85).16,18–20,25–28,30–32
Of these, seven administered only one preoperative TXA
5
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Meta-Analysis of Risk of General Complications

estimated blood loss on POD-3 (279.35 ± 209.11 vs 417.89
± 289.5; P = 0.049) and transfusion rate (28.20% vs 56.09%;
P = 0.01) in the TXA group (Table S3, http://links.lww.com/
AOSO/A85).20
Spitler et al randomized patients to receive either TXA or
placebo for hip or pelvis ORIF; patients received a 15 mg/kg
preoperative loading dose and a 15 mg/kg dose 3 hours after
initial dose.25 When excluding cell saver, total blood loss was
higher in the control group (952 vs 1,325 mL; P = 0.028) (Table
S3, http://links.lww.com/AOSO/A85).25 When including cell
saver volumes, total blood loss remained higher in the control
group (1,048 vs 1,396 mL; P = 0.046).25 The average drop in
hematocrit from preoperative to POD-1 was greater (P = 0.021)
in the control group.25 The average drop from preoperative to
POD-2 was also greater in the control group (P = 0.026; TXA
= 25.37, placebo = 27.97).25 There were no differences in major
complications.25
Batibay et al analyzed the safety and effectiveness of TXA
versus placebo administration in the setting of isolated traumatic tibial-fibular fractures requiring fixation via intramedullary nailing.32 This study excluded polytrauma, those
requiring open reduction or other orthopedic intervention,
Gustilo/Anderson type 2 or 3 open fractures, any abnormal
INR, and coagulopathies.32 The study included 35 patients in
both the control and TXA cohorts who were evaluated over
a 12-week follow-up period.32 The TXA cohort received a
10 mg/kg IV bolus 30 minutes prior to first incision.32 The Hb
levels at 24 hours (11.38 vs 10.34; P = 0.0067) and 48 hours
(10.78 vs 9.98; P = 0.0023) were significantly higher in the
TXA group.32
Dakir et al assessed the effectiveness of a single 10 mg/kg dose
of TXA versus placebo 15 minutes preoperatively in minimizing blood loss in patients undergoing maxillofacial traumatic
fractures.16 Their RCT measured Hb preoperatively and postoperatively at 4, 24, and 48 hours intervals, and both intra
and postoperative blood loss in 12 male patients (ages 20–40
years).16 They reported statistically significant reduction in
blood loss in the TXA group (489.17 vs 900.83 mL; P < 0.001)
(Table S3, http://links.lww.com/AOSO/A85).16

For the same reasons as above, only differences between in-hospital and perioperative settings were considered. In perioperative, Cohen’s Q was not significant, indicating a fixed effects
model was sufficient (Table 2). However, for in-hospital,
Cohen’s Q was significant, indicating a random effects model
was needed. There is insufficient evidence to conclude a difference between TXA and placebo complication rates in both
settings (in-hospital 95% CI: 0.26, 1.31; perioperative 95%
CI: 0.86, 2.11) (Figure S1b, http://links.lww.com/AOSO/A84).
A direct comparison of the means of the two meta-groups was
not significant (Z-test, P = 0.0779), indicating there is insufficient evidence to show a difference in RR between the in-hospital and perioperative settings.
In the single-dose subcategory, Cohen’s Q was not significant,
indicating a fixed effects model was sufficient. However, for the
Loading and Maintenance subcategory, Cohen’s Q was significant, indicating a random effects model was needed. In both
cases, there is not sufficient evidence to conclude a difference
between TXA and placebo general complication rates in either
dosing subcategory (single-dose 95% CI: 0.65, 1.70, loading
and maintenance 0.33–1.27) (Table 2; Figure S1b, http://links.
lww.com/AOSO/A84). A direct comparison of the means of the
two meta-groups was not significant (Z-test, P = 0.2536), indicating there is not sufficient evidence to show a difference in RR
between the dosing subcategories.
When all studies are considered irrespective of setting or
administration, no significant difference in incidence of complications was found between placebo and TXA.
Meta-Analysis of Risk of Venous Thromboembolism
In both cases, Cohen’s Q was not significant, indicating a fixed
effects model was sufficient. The 95% CI for the In-Hospital
setting is entirely below one (95% CI: 0.44, 0.90), indicating
there is sufficient evidence the risk of VTE in TXA-administered
patients is greater than in the placebo (Figure S1c, http://links.
lww.com/AOSO/A84). There is insufficient evidence for that
conclusion in the perioperative setting (95% CI: 0.43, 1.83)
(Table 3).
There were sufficient studies reporting VTE rates for
meta-analysis only in the single-dose subcategory. Cohen’s Q
was not significant, indicating a fixed effects model was sufficient. The meta-analysis 95% CI contains one (95% CI: 0.54,
1.09), indicating that there is insufficient evidence to conclude a
difference between TXA and placebo general complication rates
in this dosing subcategory (Figure S1c, http://links.lww.com/
AOSO/A84).
When all studies are considered irrespective of differences
in setting or administration, with the risk of VTE in placebo
patients was found to be 0.68 times that of TXA-administered
patients (95% CI: 0.49, 0.93).

Meta-Analysis
Meta-Analysis of Mortality Risk
Only two studies had the treatment cohort receive both preand in-hospital TXA.10,14 This was insufficient to perform a
meaningful meta-analysis. Thus, only in-hospital and perioperative mortality rates underwent meta-analysis (Tables 1 to 4).
In both, Cohen’s Q was not significant (Table 1), indicating a
fixed effects model was sufficient. There is insufficient evidence
to conclude a difference between TXA and placebo mortality
rates in either setting (in-hospital 95% CI: 0.86, 1.02, perioperative 0.76–2.45) (Figure S1a, http://links.lww.com/AOSO/A84).
Considering only in-hospital TBI studies, this does not change.
A direct comparison of the means of the two meta-groups was
not significant (Z-test, P = 0.2124), indicating there is not sufficient evidence to show a difference in RR between in-hospital
and perioperative settings (Figure S1a, http://links.lww.com/
AOSO/A84).
In both single-dose and loading and maintenance subcategories, Cohen’s Q was not significant, indicating a fixed effects
model was sufficient. There is sufficient evidence the risk of
mortality in TXA-administered patients is smaller than that of
the placebo (95% CI: 1.09, 2.04) (Table 1).16,18,20,21,24,26,28,31,32
However, in the Loading and Maintenance subcategory, there is
insufficient evidence of a difference between TXA and placebo
mortality rates (95% CI: 0.87, 1.02).8,14,15,17,19,22,23,29,33
When all studies are considered irrespective of setting or
administration, no significant difference in mortality was found
between Placebo and TXA.

Meta-Analysis of Risk of Infection
When all studies are considered irrespective of setting or administration, no significant difference in incidence of infection was
found between placebo and TXA. Due to insufficient number
of usable trials, we were unable to perform any comparison
meta-analyses of pre- versus in-hospital timing or dose on infection risk.
Meta-Analysis of Risk of Stroke
There was an insufficient number of usable trials to perform
comparison meta-analyses on stroke risk. When all studies are
considered irrespective of setting or administration, no significant difference in stroke incidence was found between placebo
and TXA.
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TABLE 1.
Metaestimated Mortality Risk of Placebo/TXA in In-hospital and Perioperative Settings, and in Single and Loading and Maintenance
Dosing
Category

Number of Total Number
Studies
Treatment

Subcategory

All studies
Administration Site In-hospital
In-hospital, TBI only
Perioperative
Dosing
Single dose
Loading and maintenance

12
8
6
4
6
6

Total Number
Control

Cohen’s Q
P Value

Estimated Relative Risk,
Mortality, Placebo/TXA

95% Confidence
Intervals

5320
5111
5011
209
532
5276

0.2171
0.4839
0.2912
0.1001
0.2393
0.5038

0.94
0.94
0.94
1.36
1.49
0.94

(0.87, 1.02)
(0.86, 1.02)
(0.86, 1.02)
(0.76, 2.45)
(1.09, 2.04)
(0.87, 1.02)

5427
5227
5128
200
570
5384

TXA indicates tranexamic acid.

TABLE 2.
Metaestimated Complication Risk of Placebo/TXA in In-Hospital and Perioperative Settings, and in Single and Loading & Maintenance
Dosing
Category

Number of Total Number Total Number
Studies
Treatment
Control

Subcategory

All studies
Administration site In-hospital
Perioperative
Dosing
Single dose
Loading and maintenance

9
4
5
4
5

683
423
260
475
735

674
414
260
439
723

Cohen’s Q
P Value

Estimated Relative Risk,
Any Complication, Placebo/TXA

95% Confidence
Interval

0.0127
0.0038
0.8724
0.0823
0.0080

0.61
0.59
1.34
1.05
0.65

(0.32, 1.16)
(0.26, 1.31)
(0.86, 2.11)
(0.65, 1.7)
(0.33, 1.27)

TXA indicates tranexamic acid.

TABLE 3.
Metaestimated Venous Thromboembolism Risk of Placebo/TXA in In-Hospital and Perioperative Settings, and in Single and Loading
and Maintenance Dosing
Category

Subcategory

All studies
Administration site In-hospital
Perioperative
Dosing
Single dose

Number of
Studies

Total Number
Treatment

Total Number
Control

Cohen’s Q
P Value

Estimated Relative Risk, VTE,
Placebo/TXA

95% Confidence
Interval

9
4
5
6

5106
4844
262
576

5002
4737
265
544

0.4698
0.1649
0.7684
0.2269

0.68
0.63
0.89
0.76

(0.49, 0.93)
(0.44, 0.9)
(0.43, 1.83)
(0.54, 1.09)

TXA indicates tranexamic acid; VTE, venous thromboembolism.

Meta-Analysis of Blood Loss

trial showed significant mortality benefit with early administration of TXA in mild-moderate, but not severe, TBI.8 There was
no significant difference in in-hospital mortality between TXA
and placebo groups.21,33
We also found that most studies assessing perioperative TXA
found significant reduction in intraoperative blood loss compared with placebo.16,18,20,25–28,30–32 One study reported no significant difference in blood loss.19 Meta-analysis showed a 178 mL
difference between the Control and TXA, with a 95% Student’s t
CI of (–21.6, 343.5), indicating there is not sufficient evidence to
show the blood loss for the TXA group differs from the placebo
group. There was a variable effect on ICH volume expansion in
TXA compared with placebo. Two studies reported significantly
less ICH expansion, while two others reported no significant
difference.15,17,23,29
Meta-analysis of comparison of RR of mortality between
treatment and placebo groups in in-hospital and perioperative
settings was not significant. However, when considering studies
which only administered one loading TXA bolus, the meta-CI
was >1, indicating risk of mortality is significantly lower in the
treatment group.
Meta-analysis results indicate the risk of VTE in the treatment group is greater than in the placebo in in-hospital setting.
However, there is not sufficient evidence for that conclusion in
perioperative setting, nor is there sufficient evidence to show a
difference in RR between in-hospital and perioperative settings.
There was no significant difference in RR in single-dose TXA,

All studies with Blood Loss values that included standard deviations were in the Perioperative setting.16,18–20,26,28,30,31 Cohen’s Q
was significant (P < 0.0001), indicating the need for a random
effects model. The 95% CI for the resulting difference between
the placebo and TXA means contains zero (95% CI: –22, 344),
indicating there is insufficient evidence to show that blood loss
for the TXA group differs from the placebo group (Table 4;
Figure S1d, http://links.lww.com/AOSO/A84). Analysis of the
five studies that evaluated TXA use in surgical treatment of
traumatic hip or pelvic fractures showed meta-CI containing
zero (95% CI: –20, 367). When considering the single-dose subset of these studies, the result does not change. No other dosing
subsets had enough for meaningful meat-analysis.

DISCUSSION
This systematic review and meta-analysis included 22 RCTs
evaluating TXA use in prehospital, in-hospital, and perioperative settings. Main outcomes assessed were mortality, complications, and blood loss.
The systematic review found that in adults with non-TBI
traumatic injury, prehospital TXA showed significant mortality
benefit when given ≤1 hour after injury.10 In the lone study of
TXA in TBI given prehospital, there was no significant difference in outcome, mortality, or ICH volume.14 The CRASH-3
7
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TABLE 4.
Metaestimated Difference in Blood Loss of Placebo/TXA in In-Hospital and Perioperative Settings, and in Single and Loading and
Maintenance Dosing
Category

Subcategory

Number of
Studies

Total Number
Treatment

Total Number
Control

Cohen’s Q
P Value

Estimated Difference in Blood Loss,
Placebo—TXA (mL)

95% Confidence
Interval

All studies
Administration site
Dosing
Fracture type

Perioperative
Single Dose
Hip/Pelvis

8
8
6
5

299
299
196
223

312
312
205
236

< 0.0001
< 0.0001
< 0.0001
0.0006

178
178
192
207

(-21.6, 343.54)
(-21.6, 343.54)
(-57.32, 382.97)
(-20.11, 366.95)

TXA indicates tranexamic acid.

and gender may have led to findings which cannot be attributed
to TXA use. Moreover, mortality included deaths occurring
within 30 days of intervention in some studies while others only
reported in-hospital mortality. Of note, included RCTs were
published in various international journals, with varying impact
factors. There were also differences in the number of patients
within studies. Despite our aim to include all RCTs on TXA use
in traumatic injury, studies such as the CRASH-3 trial enrolled
patients on a much larger scale than others. Consequently, a
larger proportion of patients and results were obtained from the
CRASH-3 trial.

regardless of setting. Unfortunately, there were not enough studies reporting VTE rate in other dosing protocols.
While a few prior studies have analyzed the combined results
of recent TXA RCTs, to our knowledge this is the largest systematic review and meta-analysis of 22 studies. Other reviews
include up to 12 studies.34–39 This study includes comparative
analysis of administration setting/dosing and type of injury.
Although other systematic reviews and meta-analyses, such as
the publication by Almuwallad et al, have attempted to elucidate the effect of prehospital TXA use, to our knowledge, no
other study includes only randomized controlled trials (RCTs).40
Almuwallad et al included a total of four studies: only one RCT,
one retrospective cohort, and two prospective cohorts.40
Current recommendations and guidelines are often vague and
inconclusive, partly due to gaps in the literature reporting strong
and consistent evidence for TXA in various traumatic settings
and injury types. Furthermore, because trials like the CRASH
studies were conducted outside the United States, similar studies
should be conducted in the United States to draw more conclusive evidence and provide clearer guidelines. The 2017 Eastern
Association for the Surgery of Trauma (EAST) guidelines for
damage control resuscitation and severe traumatic hemorrhage
recommended TXA for in-hospital use.41
The findings of the systematic review suggest there is some
mortality benefit associated with early TXA in trauma. These
results highlight the need for clear, concordant guidelines for
TXA in trauma. The inclusion of only RCTs provides stronger
evidence and limits risk of bias. Understanding the importance
of TXA with factors such as setting, demographics, GCS, dosage,
and timing is crucial.40 Identification of key injury patterns and
development of detailed guidelines may significantly improve
patient outcomes. This study may assist in valuation of TXA
in trauma, or at least provide indications for further research.

CONCLUSIONS
The systematic review of TXA indicates the benefits of this
intervention appear most evident when given shortly after traumatic injury. The systematic review also supports the value of
TXA in reducing intraoperative blood loss and evidence indicates it could provide more favorable outcomes when used in
emergent settings in which large volumes of blood loss are anticipated. The meta-analysis showed TXA used as a single dose
was associated with improved mortality. Meta-analysis of TXA
used in a single dose showed no significant difference in risk of
VTE or other complications compared with placebo. Cohesive
guidelines on the use of TXA are lacking; the findings of this
study may aid in the development of algorithms for identifying
patients who may benefit from TXA use.
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